舒泰神（北京）生物制药股份有限公司接待投资者调研纪要 投资管理有限公司、某个人投资者 舒泰神调研纪要 时间：2015 年 04 月 24 日 | --- | |------------------------------------------------------| | | | 光大证券、太平洋证券、东方证券、民生证券、国联证券、 | | 长城基金、天弘基金、中信产业基金、嘉实基金、摩根 | | 士丹利华鑫基金、富国基金、泰康资产、上海承周资产 | | 管理有限公司、北京嘉承金信投资有限公司、南山集团 | | 资本投资有限公司、天马资产管理有限公司、广州长金 | 接待人：马莉娜 一、董事会秘书马莉娜介绍 2015 年第一季度业绩情况： 2015 年第一季度，公司实现营业总收入 23299.18 万元，比去年 同期增长 7.76%；归属于上市公司股东的净利润为 5044.41 万元，比 去年同期增长 41.81%。 营销方面，不断强化市场工作，高度重视各省招投标、价格维 护工作；深入研究所处市场环境，针对不同区域市场制定产品策划 和学术推广策略，持续加强品牌建设；通过对销售人员能力与素质 的培训与提升，提高 ...

证券代码：300204 证券简称:舒泰神 舒泰神（北京）生物制药股份有限公司 投资者关系活动记录表 编号：2015-002 | --- | --- | --- | |--------------|--------------------------|--------------------------------------------------| | | | | | 投资者关系活 | ■ 特定对象调研 | □ 分析师会议 | | 动类别 | □ 媒体采访 | □ 业绩说明会 | | | □ 新闻发布会 | □ 路演活动 | | | □ 现场参观 | | | | □ 其他 | | | 参与单位名称 | | 光大证券、太平洋证券、东方证券、民生证券、国联证 | | | | 券、长城基金、天弘基金、中信产业基金、嘉实基金、 | | | | 摩根士丹利华鑫基金、富国基金、泰康资产、上海承周 | | | | 资产管理有限公司、北京嘉承金信投资有限公司、南 | | | | 山集团资本投资有限公司、天马资产管理有限公司、 | | | | 广州长金投资管理有限公司、某个人投资者 | | 时间 | 2015 年 04 月 ...

证券代码：300204 证券简称:舒泰神 舒泰神（北京）生物制药股份有限公司 投资者关系活动记录表 编号：2015-001 | --- | --- | --- | |--------------|--------------------------|--------------------------------------------------| | | | | | 投资者关系活 | ■ 特定对象调研 | □ 分析师会议 | | 动类别 | □ 媒体采访 | □ 业绩说明会 | | | □ 新闻发布会 | □ 路演活动 | | | □ 现场参观 | | | | □ 其他 | | | 参与单位名称 | | 信诚人寿、泰达宏利基金、瑞泰人寿、中银国际、合众 | | | | 资产、中融人寿、星石投资、南方基金、常州投资集 | | | | 团、中国人寿资产管理、上海森钵投资、江苏省建工集 | | | 团装饰工程有限公司 | | | 时间 | 2015 年 03 月 18 | 日 | | 地点 | 公司会议室 | | | 上市公司接待 | 马莉娜 | | | 人员姓名 | | | | 投资者关系活 | | 产品情况 ...

Group 1: Sales and Market Position - Su Tai Shen's Su Tai Sheng sales volume in 2014 was 4,577,919 bottles [3] - Su Tai Sheng holds the largest market share among four domestic varieties of mouse nerve growth factor [4] Group 2: Product Development and Differentiation - The human nerve growth factor developed by the company is an upgraded product of mouse nerve growth factor, utilizing recombinant gene technology [5] - The human nerve growth factor has advantages in homology compared to mouse nerve growth factor [5] Group 3: International Expansion and Strategy - The U.S. subsidiary has established its work direction, completed site leasing and renovation, and initiated personnel recruitment [5] - The Hong Kong subsidiary aims to leverage the favorable business environment for international investment and financing activities in the biopharmaceutical field [6] Group 4: Product Safety and Efficacy - Mouse nerve growth factor is currently the clearest product for direct repair of nerve damage, with fewer adverse reactions and high safety, stability, and effectiveness [6] - Su Tai Qing is safe and effective for use by elderly individuals, pregnant women, and children [6] Group 5: Research and Development Investment - R&D investment is closely related to the progress and stages of R&D projects, with the company emphasizing innovative research without compromising investment due to external factors [6]

Sales Performance - Su Tai Shen's main product, Su Tai Sheng, accounted for 90% of total sales, generating approximately 1.1 billion in revenue in 2015, leading the market with the highest share among four competitors [1] - Sales of Shu Tai Qing reached around 100 million, with a market potential of 700-800 million annually in bowel preparation, positioning it as a first-line treatment [1][2] - Shu Tai Qing's sales growth was between 10%-20%, down from previous years' growth rates of over 30% [2] Research and Development - The company focuses on research in nerve damage, with ongoing projects for second and third-generation Su Tai Sheng, and gene therapy targeting hepatitis B and HIV [2] - Clinical trial applications for these projects are expected to be submitted in the following year [2] - The company is also exploring new products, with Su Tai Sheng showing over 20% growth in the first quarter compared to previous years [3] Future Strategy - The company aims to innovate in drug development and has established subsidiaries in the US and Hong Kong for talent acquisition and investment purposes [2] - Plans to increase sales include raising unit prices and expanding market coverage, especially in response to price reductions in the bidding process [3][4] Financial Insights - In 2015, the profit growth rate was 8%, with a non-recurring profit growth rate of 10%, meeting the criteria for the first phase of the stock incentive plan [4] - The company is considering early-stage investments in projects and technologies in the US [4] Market Opportunities - The market for the new drug, Qushi Chloride Capsules, is expected to grow due to increasing public awareness and demand, particularly as it addresses a new market segment [5] - The safety profile of Qushi Chloride is favorable, as it does not cross the blood-brain barrier, enhancing patient compliance [5]

Group 1: Company Overview - Shuyatshen (Beijing) Biopharmaceutical Co., Ltd. is identified with the stock code 300204 [1] - The investor relations activity took place on November 22, 2016 [2] Group 2: Investor Relations Activities - The activity type was a specific object investigation, with participation from various investment firms including Tianfeng Securities and Dongxing Securities [2] - The main topics discussed included company operations, research and development status, investment overview, and product sales [2]

舒泰神（北京）生物制药股份有限公司接待投资者调研纪要 舒泰神调研纪要 时间：2017 年 5 月 19 日 来访单位: 东兴证券、中信建投证券、华安资产、湾流投资、相聚资 本管理有限公司、北京壹玖资产管理公司、中融国际信 托有限公司、建信基金、中冀投资、远策投资 接待人：马莉娜 一、董事会秘书马莉娜介绍 2017 年公司发展情况： 2017 年中，公司的经营没有特别大的变化。在这里我主要简单 介绍一下产品、研发及公司未来的发展战略。舒泰神主要是在研发、 生产、销售全部流程为一体的公司，这是公司主要定位。在这里我 主要说一下公司销售、研发、和未来一段时间发展情况。 销售方面，新版医保目录的出台和未来一两年的招投标政策， 会让公司的销售面临一些比较严峻的挑战。从新版医保目录（2017 版）出来以后，对于神经生长因子的安全性、有效性和质量可控性 方面是一种肯定，但医疗体制改革的大方向会给神经生长因子带来 一些需要克服的困难。在 4 个上市的鼠神经生长因子产品中，销售 格局可能会有一些的变化。舒泰清一直列在医保目录里面，公司新 上市的产品舒唯欣（曲司氯铵胶囊）现在已经进入了大约 10 家医院 来进行销售。招投标方面， ...

Group 1: Market Position and Competitive Advantage - The company holds a significant market share in the pharmaceutical industry, ranking 29th among 39 companies in the "People's Finance Innovation Drug Index" [2] - Key products, Sutai Sheng and Shuitai Qing, are positioned within the top three in the market [3] - The company has developed a comprehensive competitive advantage through years of operation in the research, production, and commercialization of innovative biopharmaceuticals [3] Group 2: Future Plans and Market Demand - The company is considering the growing market demand due to population aging and has plans to address diseases related to this demographic [3] - The 2021 revenue target is set at no less than 471.5 million yuan, with expectations to register at least three drug production licenses, including two innovative biopharmaceuticals [4] - The company aims to enhance its marketing strategies, including online and offline integration, to maintain sales performance and market share for its products [4] Group 3: Research and Development Focus - The company has established a robust R&D pipeline, focusing on innovative biopharmaceuticals, with multiple projects expected to enter the IND application stage in the coming years [5] - Current R&D efforts are concentrated on treatment for neurodegenerative diseases, infectious diseases, and autoimmune diseases [5] - The company is confident in its ability to continuously provide safe and effective therapeutic drugs through its structured R&D phases [4][5] Group 4: Acquisitions and Strategic Moves - The acquisition of 100% of Sichuan Kaikang, now renamed Sichuan Shuitai Shen Pharmaceutical Co., is aimed at enhancing the company's sales platform and operational capabilities [4] - The company is actively working to maximize the value of this platform to support its overall business development [4] Group 5: Regulatory and Market Challenges - The company anticipates that its key products, Sutai Sheng and Shuitai Qing, will not enter the national centralized procurement directory in the short term [4] - The company is closely monitoring the market for Shuitai Qing to create retail demand and mitigate the impacts of centralized procurement [4]

Group 1: Company Overview - Shuotai Shen (Beijing) Biopharmaceutical Co., Ltd. is listed under the stock code 300204 [1] - The investor relations activity took place on May 19, 2021, from 15:30 to 16:30 [2] Group 2: Investor Relations Activity - The activity was categorized as a specific object survey [2] - Participants included various financial institutions such as Guosheng Securities Research Institute, CITIC Asset Management, and others [2] Group 3: Meeting Details - The meeting was held on the Guosheng Securities conference call platform [2] - Key representatives from the company included Ms. Marina, the Secretary of the Board, and Mr. Wang Chao, the Deputy General Manager [2] Group 4: Main Content - The main content included an introduction to the company's basic situation [2] - There was an interactive Q&A session with investors [2]

R&D Investment and Development - The company reported a significant increase in R&D investment, focusing on strategic new product development and exploratory research to enhance its pipeline [6]. - The company plans to optimize its R&D structure and prioritize key projects to mitigate risks associated with drug development and market acceptance [6]. - The company is actively exploring acquisitions and collaborations to expand its R&D capabilities and product offerings [6]. - The company continues to face high risks in innovative drug development due to long cycles and significant investment requirements [6]. - The company is committed to enhancing its R&D level and carefully selecting projects to improve overall business performance [6]. - R&D investment reached CNY 165.66 million, accounting for 67.03% of operating revenue, representing a year-on-year increase of 16.95% [40]. - The company is focused on developing innovative biopharmaceuticals, including monoclonal antibodies and gene therapy drugs, targeting unmet clinical needs [33]. - The company has several ongoing projects in clinical development, including monoclonal antibody drugs for COVID-19 and other therapeutic areas [33]. - The company has established an advanced drug development technology platform, including systems for drug design, screening, and clinical evaluation [47]. - The company aims to stabilize and advance competitive R&D projects in areas such as neurological diseases and infectious diseases towards IND application [39]. - The number of R&D personnel reached 268, accounting for 33.63% of the total workforce, with 59.70% holding a master's degree or above [49]. Financial Performance - The company's operating revenue for the reporting period was ¥247.15 million, a decrease of 9.35% compared to ¥272.63 million in the same period last year [26]. - The net loss attributable to shareholders was ¥82.75 million, representing a 38.35% increase in loss from ¥59.81 million year-on-year [26]. - The net cash flow from operating activities was -¥87.15 million, a decline of 23.24% from -¥70.71 million in the previous year [26]. - The total assets at the end of the reporting period were ¥1.66 billion, down 9.03% from ¥1.83 billion at the end of the previous year [26]. - The sales revenue from the product Shutaqing was ¥168 million, accounting for 68.03% of total revenue, a decrease of 9.43% year-on-year [34]. - The sales revenue from the product Suruizheng was ¥73 million, representing 29.47% of total revenue, down 14.14% from the previous year [34]. - The company achieved operating revenue of CNY 247.15 million, with a net profit attributable to shareholders of CNY -82.75 million, reflecting a significant loss [39]. - The company's revenue for the reporting period was ¥247,153,363.23, a decrease of 9.35% compared to ¥272,632,152.83 in the same period last year [55]. - Research and development expenses increased by 16.95% to ¥165,658,472.49 from ¥141,643,313.95 year-on-year [55]. - The company reported a significant increase in net cash flow from investing activities, rising by 64.64% to ¥164,072,812.91 due to reduced purchases of financial products [55]. Market and Product Development - The company is focused on continuous innovation in its product offerings, particularly in the field of neurotrophic factors and gastrointestinal health [52]. - The company is exploring new retail models and preparing for the commercialization of potential new products, which may diversify its revenue structure in the future [40]. - The company is actively expanding its market presence in the bowel preparation and constipation management sectors, with ongoing projects in the review stage [51]. - The company has established partnerships with third-party institutions to enhance its R&D capabilities and product development [49]. - The company is addressing the risk of talent shortages by enhancing its human resource management and implementing employee incentive plans [101]. - The company is committed to strengthening its market expansion efforts and improving brand recognition in the innovative drug sector [102]. Environmental and Social Responsibility - The company reported a total of 0.2208 tons of NOX emissions, which is below the regulatory limit of 30 mg/m³ [118]. - The company has a user participation rate of 43.84% in the annual shareholders' meeting held on May 12, 2022 [108]. - The company has established a wastewater treatment station with a processing capacity of 30 tons per day, which is operating well [120]. - The company has actively participated in social responsibility initiatives, donating approximately 400,000 yuan to charitable organizations [127]. - The company received the "Environmental Integrity Unit" title in 2022, highlighting its commitment to environmental protection [125]. Corporate Governance and Compliance - The financial report is guaranteed to be accurate and complete by the company's management, ensuring accountability [4]. - The company has not reported any significant changes in its accounting firm, maintaining continuity in financial oversight [135]. - The company has not engaged in any non-operating fund occupation by controlling shareholders or related parties, ensuring financial integrity [133]. - The company has implemented measures to ensure that related party transactions do not harm shareholder interests [132]. - The company has not reported any significant changes in its controlling shareholder or actual controller during the reporting period [170]. Shareholder Information - No cash dividends or stock bonuses will be distributed to shareholders for the reporting period [7]. - The company’s total share capital was reported at 476,034,500 shares, with 97.71% being unrestricted shares [162]. - The largest shareholder, Yizhao (Beijing) Pharmaceutical Technology Co., Ltd., holds 37.15% of shares, totaling 176,832,363 shares [166]. - The total number of restricted shares at the end of the period is 5,744,193 [164]. - The report indicates that 1.97% of shares are held by Huatai Securities Asset Management, totaling 9,382,600 shares [166].